Viatris Recalls Xanax XR Lot for Dissolution Failure

Viatris Specialty LLC has initiated a nationwide voluntary recall of one lot of Xanax XR extended-release tablets after the 3-milligram medication failed to meet dissolution specifications, the Food and Drug Administration announced this week. The recall, classified by the FDA as Class II, affects 60-tablet bottles marked with lot number 8177156 and an expiration date of February 28, 2027, distributed across the United States from August 27, 2024, to May 29, 2025.

The dissolution failure means the tablets may not break down properly in the body, potentially leading to inconsistent or insufficient dosing for patients relying on the drug to manage anxiety or panic disorders. According to the FDA, a Class II recall indicates situations where adverse health consequences, if they occur, are likely to be temporary and medically reversible, with the probability of serious harm considered remote. No illnesses or adverse reactions linked to this lot have been reported as of now.

Xanax, the brand name for alprazolam, is a benzodiazepine that works by enhancing the effects of gamma-aminobutyric acid, a neurotransmitter that helps calm the central nervous system. It is one of the most...